Compare SKYW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYW | CPRX |
|---|---|---|
| Founded | 1972 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 1994 | 2006 |
| Metric | SKYW | CPRX |
|---|---|---|
| Price | $94.77 | $25.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $123.67 | $35.00 |
| AVG Volume (30 Days) | 315.5K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.20 | 28.24 |
| EPS | ★ 10.35 | 1.68 |
| Revenue | ★ $2,971,963,000.00 | $119,072,803.00 |
| Revenue This Year | $8.35 | $9.20 |
| Revenue Next Year | $3.55 | $10.51 |
| P/E Ratio | ★ $9.37 | $15.38 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $82.14 | $19.05 |
| 52 Week High | $123.94 | $26.56 |
| Indicator | SKYW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 60.90 |
| Support Level | $94.62 | $22.24 |
| Resistance Level | $95.75 | N/A |
| Average True Range (ATR) | 3.21 | 0.66 |
| MACD | 0.81 | 0.16 |
| Stochastic Oscillator | 55.70 | 81.28 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.